A Phase 2 interventional study of Matching Placebo and GRT6005 in Osteoarthritis of the Knee, sponsored by Tris Pharma, Inc.. Completed at 26 sites in 3 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-15.
Sponsored by Tris Pharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Osteoarthritis, Knee with a site in Poland — 12 open to participants now, 13 under way, 2 of them phase 3. Osteoarthritis, Knee · Poland.
Among the 77 studies in Osteoarthritis, Knee with a site in Poland, this one is the 27th largest by enrollment of the 71 interventional ones that give a count, is the only one that started in 2011, is one of 13 in phase 2, and was the 5th registered.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →12 of the 77 studies in Osteoarthritis, Knee with a site in Poland are open now. Recruiting first, the newest first:
Medical University of Warsaw · Sites in Poland
Ages 18+
Implai Sp z o.o · Sites in Poland
Ages 18+
Implai Sp z o.o · Sites in Poland
Ages 18+
Poznan University of Medical Sciences · Sites in Poland
Ages 60–100
Novo Nordisk A/S · Sites in Poland, United States, Australia and 8 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 16 · Phase 3 16 · Phase 4 10
First in 2007; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 207 is above the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 120 across the 71 interventional studies, 131 across the 6 observational. Of the 57 that completed or were terminated, 21 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 77 have an industry lead sponsor. The 10 most frequent:
Tris Pharma, Inc. is the lead sponsor of 22 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 4 (31%) have results posted.
Tris Pharma, Inc. has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteoarthritis, Knee with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07449442Poznan University of Medical SciencesSII Levels Following iPACK Block With Adductor Canal Block in Knee Arthroplasty | 2026-11-30 |
| NCT07813078University of RzeszowAnti-Gravity Treadmill Gait Training for Knee Osteoarthritis | 2026-12-31 |
| NCT07677215Poznan University of Medical SciencesACB and iPACK Blocks With Intravenous Dexamethasone and Perineural Dexmedetomidine in Total Knee Arthroplasty | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 77 studies in Osteoarthritis, Knee with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the trial is to determine whether GRT6005 is effective in patients with pain due to osteoarthritis of the knee.
The purpose of this study is to evaluate the safety, tolerability and efficacy of 3 doses of GRT6005 taken once daily for 4 weeks in outpatients with moderate-to-severe painful osteoarthritis of the knee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once daily oral administration of matching placebo for 4 weeks.
Drug: Matching Placebo
Once daily oral administration of GRT6005 for 4 weeks.
Drug: GRT6005
Once daily oral administration of GRT6005 for 4 weeks.
Drug: GRT6005
Once daily oral administration of GRT6005 for 4 weeks.
Drug: GRT6005
2 capsules of matching placebo once a day, in the morning, for a total of 28 days
2 capsules containing a total of 75 µg GRT6005 once a day, in the morning, for a total of 28 days
2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days
2 capsules containing a total of 400 µg GRT6005 once a day, in the morning, for a total of 28 days
Change from baseline in the pain intensity scores during the last week of the 4-week treatment period
Time frame: 4 weeks
Change from baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the 4 week treatment period
Time frame: 4 weeks
Change from baseline in quality of health as measured by Short Form-12 Health Survey
Time frame: 4 weeks
Response measured in percentage change of pain intensity since baseline
Time frame: 4 weeks
Leeds Sleep Evaluation Questionnaire to quantify subjective impressions of sleep and waking
Time frame: 4 weeks
Patient's Global Impression of Change (PGIC)
Time frame: 4 weeks
Clinician's Global Impression of Change (CGIC)
Time frame: 4 weeks
Weekly current pain intensity changes from baseline
Time frame: 4 weeks
Rescue medication use
Time frame: 4 weeks
Quality of Life EuroQoL-5 Dimension score, change from baseline
Time frame: 4 weeks
Clinical Opioid Withdrawal Scale
Time frame: 4 weeks
Plasma concentration
Time frame: 4 weeks
Discontinuation from study due to treatment related adverse events
Time frame: 4 weeks
Time to withdrawal from study
Time frame: 4 weeks
The record gives a start of May 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cebranopadol